openPR Logo
Press release

Investigation for Long-Term Investors in shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA)

04-14-2020 06:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) shares.

An investigation on behalf of current long term investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Portola Pharmaceuticals, Inc..

Investors who are current long term investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: PTLA stocks follows a lawsuit filed against Portola Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PTLA stocks, concerns whether certain Portola Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the Defendants failed to disclose to investors that Portola's internal control over financial reporting regarding reserve for product returns was not effective, that Portola was shipping longer-dated product with 36-month shelf life, that Portola had not established adequate reserve for returns of prior shipments of short-dated product, that, as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Long-Term Investors in shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) here

News-ID: 2010510 • Views:

More Releases from Shareholders Foundation

Lawsuit filed for Investors who lost money with shares of Enphase Energy, Inc. (NASDAQ: ENPH)
Lawsuit filed for Investors who lost money with shares of Enphase Energy, Inc. ( …
An investor, who purchased shares of Enphase Energy, Inc. (NASDAQ: ENPH), filed a lawsuit over alleged violations of Federal Securities Laws by Enphase Energy, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Enphase Energy, Inc. (NASDAQ: ENPH) have certain options and for certain investors are short and strict deadlines running. Deadline: April 20, 2026. NASDAQ: ENPH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Long-Term Investors in shares of Fiserv, Inc. (NYSE: FI)
Investigation announced for Long-Term Investors in shares of Fiserv, Inc. (NYSE: …
An investigation was announced for current long-term investors in shares of Fiserv, Inc. (NYSE: FI) concerning potential breaches of fiduciary duties by certain directors and officers of Fiserv, Inc. Investors who are current long term investors in Fiserv, Inc. (NYSE: FI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Ardent Health, Inc. (NYSE: ARDT) Investor Alert: Deadline in Lawsuit on March 09, 2026
Ardent Health, Inc. (NYSE: ARDT) Investor Alert: Deadline in Lawsuit on March 09 …
A deadline is coming up on March 09, 2026 in the lawsuit filed for certain investors of Ardent Health, Inc. (NYSE: ARDT) over alleged securities laws violations by Ardent Health, Inc. Investors who purchased shares of Ardent Health, Inc. (NYSE: ARDT) have certain options and there are strict and short deadlines running. Deadline: March 09, 2026. Ardent Health, Inc. (NYSE: ARDT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Investigation of potential Wrongdoing
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Investigation of potent …
An investigation on behalf of investors in shares of Sina Corporation (formerly NASDAQ: SINA) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors inSina Corporation (formerly NASDAQ: SINA shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in Sina Corporation (formerly NASDAQ:

All 5 Releases


More Releases for Portola

Oral Anticoagulant Market to Witness Huge Growth by 2030 | Bayer, Boehringer Ing …
HTF MI recently introduced Global Oral Anticoagulant Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market size (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Major Companies in Oral Anticoagulant Market are: Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Portola Pharmaceuticals, Sanofi, Aspen Pharmacare,
Anticoagulant Reversal Drugs Market Projected To Witness Substantial Growth, 202 …
The Latest study titled Anticoagulant Reversal Drugs Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the
Apixaban Market Overall Study Report 2025-2032 | Bristol-Myers Squibb, Portola P …
The latest report, titled "Apixaban Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032" by Coherent Market Insights, offers an in-depth analysis of the industry, providing valuable insights into market dynamics. The study perhaps a perfect mixture of qualitative and quantitative information highlighting key market developments, challenges, competition industry face alongside gap analysis and new opportunities available and trend within the Apixaban Market. This report offers Market size, recent
Apixaban Market Determine a Spectacular Expansion And Productive Impact 2022-202 …
𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 released a new market study on 2022-2028 Apixaban Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The global research report delivers an in-depth watch on leading competitors with strategic analysis, small and macro business trends and eventualities, valuation analysis and a holistic summary within the forecast amount. Its knowledge and in-depth reports specializing in primary
Lawsuit filed for Investors in shares of Portola Pharmaceuticals, Inc. (NASDAQ: …
An investor, who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), filed a lawsuit over alleged Securities Laws violations by Portola Pharmaceuticals, Inc.. Investors who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) have certain options and for certain investors are short and strict deadlines running. Deadline: March 16, 2020. NASDAQ: PTLA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. San Francisco, CA based Portola Pharmaceuticals,
Apixaban Market is Booming 2019 | Pfizer, Roche, CoaguSense, Siemens, Alere, Abb …
Apixaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market as capsules and tablet form. Increasing prevalence of venous thromboembolism related conditions is expected to aid in growth of the apixaban market. For instance, according to International Society on Thrombosis and Haemostasis 2014 facts, revealed that